Kangchen Pharmaceutical announced that it recently received a clinical trial notice for KC1086 tablets, a Class 1 innovative chemical drug approved and issued by the State Drug Administration. KC1086 is a potent, highly selective lysine acetyltransferase 6 small molecule inhibitor with a novel structure, intended for the treatment of advanced recurrent or metastatic solid tumors. KAT6 is abnormally expressed in various tumor types. Inhibiting KAT6 can effectively inhibit the growth of tumor cells or tumors, and has potential clinical application value in reversing tumor resistance and tumor treatment. KC1086 showed excellent in vivo efficacy in various CDX/PDX models of mouse transplantation; the tumor suppression rate in ER+/HER2 breast cancer pharmacodynamics models was over 90%, and similar effects were shown in other solid tumor pharmacodynamics models.

Kangchen Pharmaceutical announced that it recently received a clinical trial notice for KC1086 tablets, a Class 1 innovative chemical drug approved and issued by the State Drug Administration. KC1086 is a potent, highly selective lysine acetyltransferase 6 small molecule inhibitor with a novel structure, intended for the treatment of advanced recurrent or metastatic solid tumors. KAT6 is abnormally expressed in various tumor types. Inhibiting KAT6 can effectively inhibit the growth of tumor cells or tumors, and has potential clinical application value in reversing tumor resistance and tumor treatment. KC1086 showed excellent in vivo efficacy in various CDX/PDX models of mouse transplantation; the tumor suppression rate in ER+/HER2 breast cancer pharmacodynamics models was over 90%, and similar effects were shown in other solid tumor pharmacodynamics models.